Filtered By:
Management: Partnerships

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 1065 results found since Jan 2013.

Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine
Cancer J. 2022 Mar-Apr 01;28(2):146-150. doi: 10.1097/PPO.0000000000000587.ABSTRACTThe sudden emergence of the coronavirus disease 2019 (COVID-19) pandemic in early 2020 stimulated unprecedented scientific initiatives to rapidly develop effective treatments and vaccines. One example was the development of vaccines based on messenger RNA platforms, which received emergency use authorization in the United States less than 1 year after the primary sequence of the severe acute respiratory syndrome coronavirus 2 virus was published. Novel practices arose from the collaborative efforts and inclusive clinical studies that facilit...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Randall N Hyer Source Type: research

Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute: Cancer Research and Care
Cancer J. 2022 Mar-Apr 01;28(2):118-120. doi: 10.1097/PPO.0000000000000584.ABSTRACTThe COVID-19 (coronavirus disease 2019) pandemic has worldwide implications on health care, especially in our most vulnerable population: cancer patients. Flexibility and adaptation are needed to continue clinical research and for clinical trial development. At the Intramural Research Program, National Cancer Institute, swift changes have been implemented to protect our patients while maintaining the scientific integrity of our cancer clinical trials. Many lessons have been learned including incorporation of telehealth into clinical trials, ...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Fatima Karzai William L Dahut Source Type: research

Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine
Cancer J. 2022 Mar-Apr 01;28(2):146-150. doi: 10.1097/PPO.0000000000000587.ABSTRACTThe sudden emergence of the coronavirus disease 2019 (COVID-19) pandemic in early 2020 stimulated unprecedented scientific initiatives to rapidly develop effective treatments and vaccines. One example was the development of vaccines based on messenger RNA platforms, which received emergency use authorization in the United States less than 1 year after the primary sequence of the severe acute respiratory syndrome coronavirus 2 virus was published. Novel practices arose from the collaborative efforts and inclusive clinical studies that facilit...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Randall N Hyer Source Type: research

Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute: Cancer Research and Care
Cancer J. 2022 Mar-Apr 01;28(2):118-120. doi: 10.1097/PPO.0000000000000584.ABSTRACTThe COVID-19 (coronavirus disease 2019) pandemic has worldwide implications on health care, especially in our most vulnerable population: cancer patients. Flexibility and adaptation are needed to continue clinical research and for clinical trial development. At the Intramural Research Program, National Cancer Institute, swift changes have been implemented to protect our patients while maintaining the scientific integrity of our cancer clinical trials. Many lessons have been learned including incorporation of telehealth into clinical trials, ...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Fatima Karzai William L Dahut Source Type: research

Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine
Cancer J. 2022 Mar-Apr 01;28(2):146-150. doi: 10.1097/PPO.0000000000000587.ABSTRACTThe sudden emergence of the coronavirus disease 2019 (COVID-19) pandemic in early 2020 stimulated unprecedented scientific initiatives to rapidly develop effective treatments and vaccines. One example was the development of vaccines based on messenger RNA platforms, which received emergency use authorization in the United States less than 1 year after the primary sequence of the severe acute respiratory syndrome coronavirus 2 virus was published. Novel practices arose from the collaborative efforts and inclusive clinical studies that facilit...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Randall N Hyer Source Type: research

Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute: Cancer Research and Care
Cancer J. 2022 Mar-Apr 01;28(2):118-120. doi: 10.1097/PPO.0000000000000584.ABSTRACTThe COVID-19 (coronavirus disease 2019) pandemic has worldwide implications on health care, especially in our most vulnerable population: cancer patients. Flexibility and adaptation are needed to continue clinical research and for clinical trial development. At the Intramural Research Program, National Cancer Institute, swift changes have been implemented to protect our patients while maintaining the scientific integrity of our cancer clinical trials. Many lessons have been learned including incorporation of telehealth into clinical trials, ...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Fatima Karzai William L Dahut Source Type: research

Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine
Cancer J. 2022 Mar-Apr 01;28(2):146-150. doi: 10.1097/PPO.0000000000000587.ABSTRACTThe sudden emergence of the coronavirus disease 2019 (COVID-19) pandemic in early 2020 stimulated unprecedented scientific initiatives to rapidly develop effective treatments and vaccines. One example was the development of vaccines based on messenger RNA platforms, which received emergency use authorization in the United States less than 1 year after the primary sequence of the severe acute respiratory syndrome coronavirus 2 virus was published. Novel practices arose from the collaborative efforts and inclusive clinical studies that facilit...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Randall N Hyer Source Type: research

Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute: Cancer Research and Care
Cancer J. 2022 Mar-Apr 01;28(2):118-120. doi: 10.1097/PPO.0000000000000584.ABSTRACTThe COVID-19 (coronavirus disease 2019) pandemic has worldwide implications on health care, especially in our most vulnerable population: cancer patients. Flexibility and adaptation are needed to continue clinical research and for clinical trial development. At the Intramural Research Program, National Cancer Institute, swift changes have been implemented to protect our patients while maintaining the scientific integrity of our cancer clinical trials. Many lessons have been learned including incorporation of telehealth into clinical trials, ...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Fatima Karzai William L Dahut Source Type: research

Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine
Cancer J. 2022 Mar-Apr 01;28(2):146-150. doi: 10.1097/PPO.0000000000000587.ABSTRACTThe sudden emergence of the coronavirus disease 2019 (COVID-19) pandemic in early 2020 stimulated unprecedented scientific initiatives to rapidly develop effective treatments and vaccines. One example was the development of vaccines based on messenger RNA platforms, which received emergency use authorization in the United States less than 1 year after the primary sequence of the severe acute respiratory syndrome coronavirus 2 virus was published. Novel practices arose from the collaborative efforts and inclusive clinical studies that facilit...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Randall N Hyer Source Type: research

Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute: Cancer Research and Care
Cancer J. 2022 Mar-Apr 01;28(2):118-120. doi: 10.1097/PPO.0000000000000584.ABSTRACTThe COVID-19 (coronavirus disease 2019) pandemic has worldwide implications on health care, especially in our most vulnerable population: cancer patients. Flexibility and adaptation are needed to continue clinical research and for clinical trial development. At the Intramural Research Program, National Cancer Institute, swift changes have been implemented to protect our patients while maintaining the scientific integrity of our cancer clinical trials. Many lessons have been learned including incorporation of telehealth into clinical trials, ...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Fatima Karzai William L Dahut Source Type: research

Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine
Cancer J. 2022 Mar-Apr 01;28(2):146-150. doi: 10.1097/PPO.0000000000000587.ABSTRACTThe sudden emergence of the coronavirus disease 2019 (COVID-19) pandemic in early 2020 stimulated unprecedented scientific initiatives to rapidly develop effective treatments and vaccines. One example was the development of vaccines based on messenger RNA platforms, which received emergency use authorization in the United States less than 1 year after the primary sequence of the severe acute respiratory syndrome coronavirus 2 virus was published. Novel practices arose from the collaborative efforts and inclusive clinical studies that facilit...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Randall N Hyer Source Type: research

Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute: Cancer Research and Care
Cancer J. 2022 Mar-Apr 01;28(2):118-120. doi: 10.1097/PPO.0000000000000584.ABSTRACTThe COVID-19 (coronavirus disease 2019) pandemic has worldwide implications on health care, especially in our most vulnerable population: cancer patients. Flexibility and adaptation are needed to continue clinical research and for clinical trial development. At the Intramural Research Program, National Cancer Institute, swift changes have been implemented to protect our patients while maintaining the scientific integrity of our cancer clinical trials. Many lessons have been learned including incorporation of telehealth into clinical trials, ...
Source: Cancer Journal - March 25, 2022 Category: Cancer & Oncology Authors: Fatima Karzai William L Dahut Source Type: research

Coronavirus (COVID-19) Infection Survey, antibody data, UK: 24 March 2022, ONS
This study is jointly led by the Office for National Statistics (ONS) and the Department for Health and Social Care (DHSC) working with the University of Oxford and Lighthouse Laboratory to collect and test samples.
Source: Current Awareness Service for Health (CASH) - March 24, 2022 Category: Consumer Health News Source Type: news

Narratives from African American/Black, American Indian/Alaska Native, and Hispanic/Latinx community members in Arizona to enhance COVID-19 vaccine and vaccination uptake
This report describes results from 34 virtually-held focus groups and supplemental survey responses conducted with 153 AA/B, HLX, and Native community members across Arizona to understand factors associated with COVID-19 vaccine hesitancy and confidence. Focus groups revealed common themes of vaccine hesitancy stemming from past experiences of research abuses (e.g., Tuskegee syphilis experiment) as well as group-specific factors. Across all focus groups, participants strongly recommended the use of brief, narrative vaccination testimonials from local officials, community members, and faith leaders to increase trust in scie...
Source: Journal of Behavioral Medicine - March 24, 2022 Category: Psychiatry Source Type: research